Human stem cells for modeling heart disease and for drug discovery

Science Translational Medicine

Volumn 6, Issue 239, 2014, Pages

  Matsa, Elena ^a   Burridge, Paul W ^a   Wu, Joseph C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ACTIVIN A; ASCORBIC ACID; BONE MORPHOGENETIC PROTEIN 4; CHIR 99021; CISAPRIDE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; MEXILETINE; NICOTINAMIDE; PROCAINAMIDE; PROPRANOLOL; QUINIDINE; ROSCOVITINE; SERTINDOLE; SOTALOL; TERFENADINE; UNCLASSIFIED DRUG; VERAPAMIL;

ADULT STEM CELL; CARDIAC CHANNELOPATHY; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL TRANSDIFFERENTIATION; DRUG EFFECT; DRUG RESEARCH; DRUG SCREENING; EMBRYONIC STEM CELL; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; HEART DISEASE; HEART INFARCTION; HEART MUSCLE CELL; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; LONG QT SYNDROME 1; LONG QT SYNDROME 2; LONG QT SYNDROME 3; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TISSUE REGENERATION; TOXICITY TESTING; BIOLOGICAL MODEL; CYTOLOGY; DRUG DEVELOPMENT; HEART DISEASES; WOUND HEALING;

DRUG DISCOVERY; HEART DISEASES; HUMANS; MODELS, CARDIOVASCULAR; STEM CELL TRANSPLANTATION; STEM CELLS; WOUND HEALING;

EID: 84903196154     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008921     Document Type: Review

References (56)

1. L. J. Laslett, P. Alagona, Jr, B. A. Clark, 3rd, J. P. Drozda, Jr, F. Saldivar, S. R. Wilson, C. Poe, M. Hart, The worldwide environment of cardiovascular disease: Prevalence, diagnosis, therapy, and policy issues: A report from the American College of Cardiology. J. Am. Coll. Cardiol. 60, S1-S49 (2012).
2. World Health Organization (WHO), World Health Stat. Rep. (2008); http://www.who.int/gho/publications/world-health-statistics/EN-WHS08-Full.pdf.
3. W. H. Frishman, β-Adrenergic blockade in cardiovascular disease. J. Cardiovasc. Pharmacol. Ther. 18, 310-319 (2013).
4. + cells minimally contribute cardiomyocytes to the heart. Nature 509, 337-341 (2014).
5. M. G. Perino, S. Yamanaka, J. Li, A. M. Wobus, K. R. Boheler, Cardiomyogenic stem and progenitor cell plasticity and the dissection of cardiopoiesis. J. Mol. Cell. Cardiol. 45, 475-494 (2008).
6. R. R. Makkar, R. R. Smith, K. Cheng, K. Malliaras, L. E. J. Thomson, D. Berman, L. S. C. Czer, L. Marbán, A. Mendizabal, P. V. Johnston, S. D. Russell, K. H. Schuleri, A. C. Lardo, G. Gerstenblith, E. Marbán, Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. Lancet 379, 895-904 (2012).
7. D. Dey, L. Han, M. Bauer, F. Sanada, A. Oikonomopoulos, T. Hosoda, K. Unno, P. De Almeida, A. Leri, J. C. Wu, Dissecting the molecular relationship among various cardiogenic progenitor cells. Circ. Res. 112, 1253-1262 (2013).
8. E. Matsa, K. Sallam, J. C. Wu, Cardiac stem cell biology: Glimpse of the past, present, and future. Circ. Res. 114, 21-27 (2014).
9. Z. Lin, W. Pu, Strategies for cardiac regeneration and repair. Sci. Transl. Med. 6, 239rv1 (2014).
10. K. Kikuchi, K. D. Poss, Cardiac regenerative capacity and mechanisms. Annu. Rev. Cell Dev. Biol. 28, 719-741 (2012).
11. A. A. Kocher, M. D. Schuster, M. J. Szabolcs, S. Takuma, D. Burkhoff, J. Wang, S. Homma, N. M. Edwards, S. Itescu, Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7, 430-436 (2001).
12. M. Ieda, J. D. Fu, P. Delgado-Olguin, V. Vedantham, Y. Hayashi, B. G. Bruneau, D. Srivastava, Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142, 375-386 (2010).
13. J.-D. Fu, N. R. Stone, L. Liu, C. I. Spencer, L. Qian, Y. Hayashi, P. Delgado-Olguin, S. Ding, B. G. Bruneau, D. Srivastava, Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state. Stem Cell Rev. 1, 235-247 (2013).
14. Y. J. Nam, K. Song, X. Luo, E. Daniel, K. Lambeth, K. West, J. A. Hill, J. M. DiMaio, L. A. Baker, R. Bassel-Duby, E. N. Olson, Reprogramming of human fibroblasts toward a cardiac fate. Proc. Natl. Acad. Sci. U.S.A. 110, 5588-5593 (2013).
15. J. X. Chen, M. Krane, M. A. Deutsch, L. Wang, M. Rav-Acha, S. Gregoire, M. C. Engels, K. Rajarajan, R. Karra, E. D. Abel, J. C. Wu, D. Milan, S. M. Wu, Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. Circ. Res. 111, 50-55 (2012).
16. J. A. Efe, S. Hilcove, J. Kim, H. Zhou, K. Ouyang, G. Wang, J. Chen, S. Ding, Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat. Cell Biol. 13, 215-222 (2011).
17. K. Takahashi, K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda, S. Yamanaka, Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007).
18. + cardiomyogenic progenitor derived from the first heart field and human pluripotent stem cells. Nat. Cell Biol. 15, 1098-1106 (2013).
19. R. Ardehali, S. R. Ali, M. A. Inlay, O. J. Abilez, M. Q. Chen, T. A. Blauwkamp, M. Yazawa, Y. Gong, R. Nusse, M. Drukker, I. L. Weissman, Prospective isolation of human embryonic stem cell-derived cardiovascular progenitors that integrate into human fetal heart tissue. Proc. Natl. Acad. Sci. U.S.A. 110, 3405-3410 (2013).
20. X. H. Parsons, Y. D. Teng, J. F. Parsons, E. Y. Snyder, D. B. Smotrich, D. A. Moore, Efficient derivation of human cardiac precursors and cardiomyocytes from pluripotent human embryonic stem cells with small molecule induction. J. Vis. Exp. 57, e3274 (2011).
21. N. Cao, H. Liang, J. Huang, J. Wang, Y. Chen, Z. Chen, H.-T. Yang, Highly efficient induction and long-term maintenance of multipotent cardiovascular progenitors from human pluripotent stem cells under defined conditions. Cell Res. 23, 1119-1132 (2013).
22. E. Sachlos, D. T. Auguste, Embryoid body morphology influences diffusive transport of inductive biochemicals: A strategy for stem cell differentiation. Biomaterials 29, 4471-4480 (2008).
23. I. Kehat, D. Kenyagin-Karsenti, M. Snir, H. Segev, M. Amit, A. Gepstein, E. Livne, O. Binah, J. Itskovitz-Eldor, L. Gepstein, Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J. Clin. Invest. 108, 407-414 (2001).
24. P. W. Burridge, G. Keller, J. D. Gold, J. C. Wu, Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 10, 16-28 (2012).
25. M. A. Laflamme, K. Y. Chen, A. V. Naumova, V. Muskheli, J. A. Fugate, S. K. Dupras, H. Reinecke, C. Xu, M. Hassanipour, S. Police, C. O'Sullivan, L. Collins, Y. Chen, E. Minami, E. A. Gill, S. Ueno, C. Yuan, J. Gold, C. E. Murry, Cardiomyocytes derived from human embryonic stem cells in prosurvival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 25, 1015-1024 (2007).
26. M. Brandenburger, J. Wenzel, R. Bogdan, D. Richardt, F. Nguemo, M. Reppel, J. Hescheler, H. Terlau, A. Dendorfer, Organotypic slice culture from human adult ventricular myocardium. Cardiovasc. Res. 93, 50-59 (2012).
27. D. Rajamohan, E. Matsa, S. Kalra, J. Crutchley, A. Patel, V. George, C. Denning, Current status of drug screening and disease modelling in human pluripotent stem cells. Bioessays 35, 281-298 (2013).
28. S. R. Braam, R. Passier, C. L. Mummery, Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. Trends Pharmacol. Sci. 30, 536-545 (2009).
29. N. M. Mordwinkin, A. S. Lee, J. C. Wu, Patient-specific stem cells and cardiovascular drug discovery. JAMA 310, 2039-2040 (2013).
30. A. W. Feinberg, C. M. Ripplinger, P. van der Meer, S. P. Sheehy, I. Domian, K. R. Chien, K. K. Parker, Functional differences in engineered myocardium from embryonic stem cell-derived versus neonatal cardiomyocytes. Stem Cell Rev. 1, 387-396 (2013).
31. J. Q. He, Y. Ma, Y. Lee, J. A. Thomson, T. J. Kamp, Human embryonic stem cells develop into multiple types of cardiac myocytes: Action potential characterization. Circ. Res. 93, 32-39 (2003).
32. X. Yang, L. Pabon, C. E. Murry, Engineering adolescence: Maturation of human pluripotent stem cell-derived cardiomyocytes. Circ. Res. 114, 511-523 (2014).
33. D. Zhang, I. Y. Shadrin, J. Lam, H. Q. Xian, H. R. Snodgrass, N. Bursac, Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials 34, 5813-5820 (2013).
34. A. Mihic, J. Li, Y. Miyagi, M. Gagliardi, S. H. Li, J. Zu, R. D. Weisel, G. Keller, R. K. Li, The effect of cyclic stretch on maturation and 3D tissue formation of human embryonic stem cell-derived cardiomyocytes. Biomaterials 35, 2798-2808 (2014).
35. E. Matsa, C. Denning, In vitro uses of human pluripotent stem cell-derived cardiomyocytes. J. Cardiovasc. Transl. Res. 5, 581-592 (2012).
36. P. Liang, F. Lan, A. S. Lee, T. Gong, V. Sanchez-Freire, Y. Wang, S. Diecke, K. Sallam, J. W. Knowles, P. J. Wang, P. K. Nguyen, D. M. Bers, R. C. Robbins, J. C. Wu, Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127, 1677-1691 (2013).
37. S. R. Braam, L. Tertoolen, A. van de Stolpe, T. Meyer, R. Passier, C. L. Mummery, Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. (Amst.) 4, 107-116 (2010).
38. S. Schaaf, A. Shibamiya, M. Mewe, A. Eder, A. Stöhr, M. N. Hirt, T. Rau, W. H. Zimmermann, L. Conradi, T. Eschenhagen, A. Hansen, Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLOS ONE 6, e26397 (2011).
39. H. Sekine, T. Shimizu, K. Sakaguchi, I. Dobashi, M. Wada, M. Yamato, E. Kobayashi, M. Umezu, T. Okano, In vitro fabrication of functional three-dimensional tissues with perfusable blood vessels. Nat Commun 4, 1399 (2013).
40. E. Matsa, J. E. Dixon, C. Medway, O. Georgiou, M. J. Patel, K. Morgan, P. J. Kemp, A. Staniforth, I. Mellor, C. Denning, Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. Eur. Heart J. 35, 1078-1087 (2014).
41. A. Moretti, M. Bellin, A. Welling, C. B. Jung, J. T. Lam, L. Bott-Flügel, T. Dorn, A. Goedel, C. Höhnke, F. Hofmann, M. Seyfarth, D. Sinnecker, A. Schömig, K. L. Laugwitz, Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 363, 1397-1409 (2010).
42. E. Matsa, D. Rajamohan, E. Dick, L. Young, I. Mellor, A. Staniforth, C. Denning, Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur. Heart J. 32, 952-962 (2011).
43. D. Ma, H. Wei, Y. Zhao, J. Lu, G. Li, N. B. Sahib, T. H. Tan, K. Y. Wong, W. Shim, P. Wong, S. A. Cook, R. Liew, Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. Int. J. Cardiol. 168, 5277-5286 (2013).
44. C. Terrenoire, K. Wang, K. W. Tung, W. K. Chung, R. H. Pass, J. T. Lu, J. C. Jean, A. Omari, K. J. Sampson, D. N. Kotton, G. Keller, R. S. Kass, Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J. Gen. Physiol. 141, 61-72 (2013).
45. M. Yazawa, B. Hsueh, X. Jia, A. M. Pasca, J. A. Bernstein, J. Hallmayer, R. E. Dolmetsch, Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471, 230-234 (2011).
46. X. Carvajal-Vergara, A. Sevilla, S. L. D'Souza, Y. S. Ang, C. Schaniel, D. F. Lee, L. Yang, A. D. Kaplan, E. D. Adler, R. Rozov, Y. Ge, N. Cohen, L. J. Edelmann, B. Chang, A. Waghray, J. Su, S. Pardo, K. D. Lichtenbelt, M. Tartaglia, B. D. Gelb, I. R. Lemischka, Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465, 808-812 (2010).
47. I. Itzhaki, L. Maizels, I. Huber, A. Gepstein, G. Arbel, O. Caspi, L. Miller, B. Belhassen, E. Nof, M. Glikson, L. Gepstein, Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. J. Am. Coll. Cardiol. 60, 990-1000 (2012).
48. D. Jacoby, W. J. McKenna, Genetics of inherited cardiomyopathy. Eur. Heart J. 33, 296-304 (2012).
49. N. Sun, M. Yazawa, J. Liu, L. Han, V. Sanchez-Freire, O. J. Abilez, E. G. Navarrete, S. Hu, L. Wang, A. Lee, A. Pavlovic, S. Lin, R. Chen, R. J. Hajjar, M. P. Snyder, R. E. Dolmetsch, M. J. Butte, E. A. Ashley, M. T. Longaker, R. C. Robbins, J. C. Wu, Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 4, 130ra47 (2012).
50. C. W. Siu, Y. K. Lee, J. C. Ho, W. H. Lai, Y. C. Chan, K. M. Ng, L. Y. Wong, K. W. Au, Y. M. Lau, J. Zhang, K. W. Lay, A. Colman, H. F. Tse, Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells. Aging 4, 803-822 (2012).
51. F. Lan, A. S. Lee, P. Liang, V. Sanchez-Freire, P. K. Nguyen, L. Wang, L. Han, M. Yen, Y. Wang, N. Sun, O. J. Abilez, S. Hu, A. D. Ebert, E. G. Navarrete, C. S. Simmons, M. Wheeler, B. Pruitt, R. Lewis, Y. Yamaguchi, E. A. Ashley, D. M. Bers, R. C. Robbins, M. T. Longaker, J. C. Wu, Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12, 101-113 (2013).
52. C. Kim, J. Wong, J. Wen, S. Wang, C. Wang, S. Spiering, N. G. Kan, S. Forcales, P. L. Puri, T. C. Leone, J. E. Marine, H. Calkins, D. P. Kelly, D. P. Judge, H. S. Chen, Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 494, 105-110 (2013).
53. Y. Jiang, S. Habibollah, K. Tilgner, J. Collin, T. Barta, J. Y. Al-Aama, L. Tesarov, R. Hussain, A. W. Trafford, G. Kirkwood, E. Sernagor, C. G. Eleftheriou, S. Przyborski, M. Stojkovic, M. Lako, B. Keavney, L. Armstrong, An induced pluripotent stem cell model of hypoplastic left heart syndrome (HLHS) reveals multiple expression and functional differences in HLHS-derived cardiac myocytes. Stem Cells Translational Medicine, 10.5966/sctm.2013-0105 (2014).
54. J. M. Churko, G. L. Mantalas, M. P. Snyder, J. C. Wu, Overview of high throughput sequencing technologies to elucidate molecular pathways in cardiovascular diseases. Circ. Res. 112, 1613-1623 (2013).
55. Y. Wang, W. Y. Zhang, S. Hu, F. Lan, A. S. Lee, B. Huber, L. Lisowski, P. Liang, M. Huang, P. E. de Almeida, J. H. Won, N. Sun, R. C. Robbins, M. A. Kay, F. D. Urnov, J. C. Wu, Genome editing of human embryonic stem cells and induced pluripotent stem cells with zinc finger nucleases for cellular imaging. Circ. Res. 111, 1494-1503 (2012).
56. C. Lenfant, Prospects of personalized medicine in cardiovascular diseases. Metabolism 62, (Suppl 1), S6-S10 (2013).